Inventor
BRYSCH WOLFGANG
DE18 patents
⚠️ This page may combine multiple inventors who share the name “BRYSCH WOLFGANG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
METRIOPHARM AG
6 patentsUS11007192B2May 18, 2021
Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
METRIOPHARM AG2 citations62
US11111218B2Sep 7, 2021
Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
METRIOPHARM AG0 citations56
US10258620B2Apr 16, 2019
Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
METRIOPHARM AG1 citations55
US12122753B2Oct 22, 2024
Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
METRIOPHARM AG0 citations46
US11203575B2Dec 21, 2021
Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
METRIOPHARM AG0 citations46
US9079863B2Jul 14, 2015
Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
METRIOPHARM AG1 citations45
BIOGNOSTIK GES
5 patentsUS6455689B1Sep 24, 2002
Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
BIOGNOSTIK GES49 citations92
US7667027B2Feb 23, 2010
Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)
BIOGNOSTIK GES15 citations87
US6972171B1Dec 6, 2005
Antisense oligonucleotide preparation method
BIOGNOSTIK GES14 citations82
US7563778B2Jul 21, 2009
Antisense oligonucleotide preparation method
BIOGNOSTIK GES2 citations61
US7326783B2Feb 5, 2008
Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
BIOGNOSTIK GES0 citations45